Dec. 12, 2008
Biotech has a new model: Nektar Therapeutics Inc.
A one-trick pony considered on the brink of disaster 14 months ago, Nektar now has a deep pipeline of early- and mid-stage drugs, less debt, more cash and a slimmed-down workforce.
That puts the San Carlos company in a good position to weather the credit and investment storm drenching other biotech companies today.
Friday, October 30, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment